Table of ContentsView AllTable of ContentsThe PeritoneumSymptomsCauses/Risk FactorsDiagnosisTreatmentPrognosisCoping
Table of ContentsView All
View All
Table of Contents
The Peritoneum
Symptoms
Causes/Risk Factors
Diagnosis
Treatment
Prognosis
Coping
Peritoneal cancer, also called primary peritoneal cancer, is a rare type of cancer, occurring in fewer than seven out of every million people in the United States.
The peritoneum is a membrane that lines the abdominal cavity. It houses the digestive tract, liver, and other organs. Peritoneal cancer can first begin in the abdominal cavity (known as primary peritoneal cancer) or spread to the peritoneum from cancer that started elsewhere.
Symptoms of peritoneal cancer are often vague, making it difficult to diagnose until the cancer is advanced. It is often fatal, though new treatments for peritoneal cancer are improving survival rates.
This article details the anatomy of the peritoneum and how peritoneal cancer is diagnosed and treated.
Istockphoto.com/Stock Photo/Ridofranz
The Peritoneum Lines the Abdominal Cavity
The peritoneum is a two-layered membrane composed of epithelial cells. It lines the abdominal and pelvic cavity organs, covering the digestive tract, liver, and reproductive organs.
The peritoneal membranes and the fluid between the membranes protect the organs, allowing them to move freely against each other without sticking or rubbing.
Some other forms of cancer can spread to the peritoneum, but peritoneal cancer beginswithinthe cells that make up the peritoneum (the reason it’s calledprimaryperitoneal cancer).
Peritoneal cancer may develop anywhere within the abdominal or pelvic cavity and, when it spreads, it often spreads to the surface of abdominal and pelvic organs.
Symptoms of Peritoneal Cancer
People with peritoneal cancer often have few symptoms until the disease is fairly advanced.
When symptoms occur, they are often vague and nonspecific and include fatigue, abdominal swelling, diffuse abdominal pain, urinary frequency, and a sense of fullness when eating.
Other symptoms may include constipation, bowel changes, abnormal vaginal bleeding, an abdominal mass, orunintentional weight loss.
As the disease progresses, complications can include:
What Is a Bowel Obstruction?
Causes and Risk Factors for Peritoneal Cancer
It’s not known precisely what causes peritoneal cancer, though the process begins when a series of mutations in peritoneal cells results in out-of-control growth.
Peritoneal cancer is much more common in females than males and has risk factors similar to therisk factors for ovarian cancer.
Risk factors include:
Using talc below the waist is also linked with an increased risk.
In contrast, some factors are associated with a decreased risk of developing the disease. These include using oral contraceptives (the reduced risk may last 30 years after they are discontinued), having a tubal ligation, giving birth (especially before age 35), and breastfeeding.
A few studies suggest that the use of aspirin and nonsteroidal anti-inflammatory drugs such as Advil (ibuprofen) may reduce risk.
Hysterectomy: Overview
Genetics
A family history of ovarian, fallopian tube, or peritoneal cancer increases the risk of peritoneal cancer, and around 10% of these cancers are considered to be hereditary. Having certain genetic syndromes such asLynch syndrome (hereditary non-polyposis colon cancer)or having a BRCA gene mutation increases the risk.
Women who carry a BRCA gene mutation have roughly a 5% risk of developing peritoneal cancer, even if their ovaries have been removed preventively.
Primary Peritoneal Cancer vs. Ovarian Cancer
Up to 15% of advanced serousovarian cancerpatients could have primary peritoneal cancer.
There are many similarities between primary peritoneal cancer and epithelial ovarian cancer, including similar symptoms, microscopic appearance, and each condition’s response to similar treatment methods.
The similarity between these two types of cancer helps plan treatment, as more research has been done on epithelial ovarian cancer because it’s much more common. Epithelial ovarian cancer occurs in roughly 120 out of 1 million people.
While peritoneal and ovarian cancers are similar, there are also significant differences.For example, people diagnosed with peritoneal cancer tend to be older than those with ovarian cancer.
The peritoneum and the surface of the ovarian stem form from the same tissue in fetal development. There is some thought that the peritoneal cells that give rise to peritoneal cancer may be leftover ovarian cells that remained in the abdomen during development.
The chance that debulking surgery will be successful is greater in peritoneal cancer than in ovarian cancer, but the overall survival rate is worse for peritoneal cancer.
Diagnosing Peritoneal Cancer
No screening test has been found effective in the early detection of primary peritoneal cancer, even for those with an elevated risk of developing the disease.
After listening to symptoms and performing a physical exam, there are severaltests doctors may orderwhen considering the diagnosis.
Blood Tests
The blood test CA-125 checks the level of a tumor marker that may be elevated in people with peritoneal cancer.That said, levels of CA-125 may be elevated in many conditions, from pelvic infections to pregnancy, and levels may be normal even in the presence of cancer.
Tumor Markers: Role in Cancer Diagnosis and Treatment
Imaging Tests
Imaging studies can help evaluate the symptoms of peritoneal cancer. An ultrasound (transvaginal ultrasound) is often the first test performed. A computerized tomography (CT) scan or magnetic resonance imaging (MRI) scan of the abdomen and pelvis may also be helpful.
In addition, an upper and or lower GI series may be ordered.
Biopsy and Laparoscopy
Most often, a biopsy is needed for a definitive diagnosis. When ascites are present,paracentesismay be done. A needle is inserted through the skin into the abdominal cavity to drain fluid. This fluid can be examined under a microscope to look for the presence of cancer cells.
A laparoscopy may also help guide treatment. A 2018 study found that laparoscopy was very sensitive in determining who would likely respond well to more extensive surgery.
A biopsy is often taken during a laparoscopy, a minimally invasive procedure in which several small incisions are made in the abdomen, and instruments are inserted to remove tissue samples from the abdomen or pelvis.
Exploratory Laparotomy: Overview
Differential Diagnosis
Several conditions can mimic primary peritoneal cancer. Some of these include the different types of ovarian cancer, abdominal abscesses, cystic collection of fluid, bile, or lymph fluid, and metastases to the peritoneum from other types of cancer.
Staging
Unlike many cancers that are classified into stages from 1 to 4, primary peritoneal cancer does not have an early stage.
This disease is always defined as stage 3 or stage 4 at diagnosis.
Types of Cancer and How They Differ
Peritoneal Cancer Treatment Options
The treatment for peritoneal cancer will depend on a number of factors, including the location of the cancer, the stage, and a person’s general health.
Surgery
The surgery most often performed is cytoreduction or debulking surgery. The goal is to remove an optimal amount of cancer, but it’s often impossible to remove all of the cancer.The peritoneum itself cannot be removed.
After optimal cytoreductive surgery, there are not any areas of cancer left in the abdomen that are larger than 1 centimeter (about half an inch) in diameter. By reducing the amount of tumor present, survival improves, and chemotherapy can be more effective, as it works better if there are only small tumors in the abdomen.
Since optimal cytoreduction surgery is a major procedure, a preliminary laparoscopy may be helpful in deciding if the risks outweigh the benefits.
During cytoreduction surgery, the surgeon removes all visible tumors. If the tumor cannot be separated from an organ, it may be partially or completely removed. This may include the gallbladder, spleen, part of the small or large intestine, theuterus, fallopian tubes, ovaries, and the primary location of cancer in the peritoneum. Sometimes the omentum, the fatty layer of tissue surrounding the intestines, is also removed (omentectomy).
Understanding Ascites
Chemotherapy
Chemotherapyis commonly used for treating peritoneal cancer. It can be started during or after surgery, or used alone for tumors that are widespread. Chemotherapy can be given intravenously or injected directly into the abdominal cavity (intraperitoneal chemotherapy).
Hyperthermic intraperitoneal chemotherapy is a fairly unique treatment that has proven beneficial for peritoneal cancer.
During this procedure, chemotherapy drugs are heated to 107.6 degrees F prior to being injected into the abdomen. Heat can kill cancer cells and may make chemotherapy more effective. It is most often used shortly after cytoreductive surgery has been completed for advanced peritoneal cancer.
Immunotherapy may be used in some cases.
Targeted Therapies
A class of drugs called PARP inhibitors, which inhibit the poly ADP ribose polymerase enzyme, may be used for women who carry BRCA gene mutations. The PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib) are approved for treating this type of cancer.
Everything You Need to Know About HER2-Positive vs. HER2-Negative Breast Cancer
Radiation
Radiation is used infrequently for peritoneal cancer but may sometimes be useful for treating isolated areas of cancer.
What Is the Purpose of Clinical Trials?
Supportive/Palliative Care
Most people are diagnosed with peritoneal cancer only after it is in the advanced stages, when a cure is not possible. Yet, there are many things that can be done to improve quality of life.
Alternative treatments have not been found to be effective for treating cancer but may help people cope with the symptoms related to cancer and cancer treatments. Integrative therapies, such as yoga, meditation, massage, acupuncture, and more, are offered at many cancer centers.
While the prognosis of peritoneal cancer is generally poor, there have been documented cases of complete remission from the disease.
There are few studies looking at survival rates, and factors associated with better survival rates include the absence of cancer in the lymph nodes and complete cytoreduction surgery.
Coping with cancer is challenging, and the fact that many people have never heard of peritoneal cancer can add to the stress and anxiety of having this diagnosis. This can feel very isolating, especially when you see the communal support offered to people with other types of cancer.
While you are unlikely to find a support group for peritoneal cancer in your community due to the relative rarity of the disease, it is possible to connect with peritoneal cancer communities online.
In addition to these resources, some of the cancer organizations that represent ovarian cancer, as well as organizations that support people with many forms of cancer, may also be a source of support. Some, likeCancerCare, even provide support groups and communities for friends and family members of people living with cancer as well.
Summary
Peritoneal cancer is a rare cancer that forms in the lining of the abdominal cavity, known as the peritoneum. Symptoms of peritoneal cancer are often vague and include fatigue, abdominal pain and swelling, urinary frequency, and a sense of fullness when eating.
10 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Yun WS, Bae JM.Primary peritoneal serous carcinoma, an extremely rare malignancy: a case report and review of the literature.Oncol Lett. 2016;11(6):4063–4065. doi:10.3892/ol.2016.4525Veron Sanchez A, Bennouna I, Coquelet N, et al.Unravelling peritoneal carcinomatosis using cross-sectional imaging modalities.Diagnostics (Basel). 2023;13(13):2253. doi:10.3390/diagnostics13132253National Cancer Institute.Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ)—health professional version.Gao B, Lindemann K, Anderson L, et al.Serous ovarian and primary peritoneal cancers: a comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.Gynecol Oncol. 2016;142(3):458-464. doi:10.1016/j.ygyno.2016.06.023Bintintan VV, Cordoş A, Chira R, et al.The value of staging laparoscopy for optimal multidisciplinary treatment in patients with gastric cancer.Chirurgia (Bucur). 2018;113(6):789-798. doi:10.21614/chirurgia.113.6.789Andikyan V, Kim A, Gretz HF 3rd, et al.Laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction in patients undergoing primary debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer.Am J Clin Oncol. 2018;41(10):938-942. doi:10.1097/COC.0000000000000413Tufts Medical Center.Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).Kurnit KC, Coleman RL, Westin SN.Using PARP inhibitors in the treatment of patients with ovarian cancer.Curr Treat Options Oncol. 2018;19(12):1. doi:10.1007/s11864-018-0572-7Lee J, Turetsky J, Nasri E, Rogers SC.Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.BMJ Case Rep. 2023;16(12):e255916. doi:10.1136/bcr-2023-255916Sedighim S, Khan A, Li AY, et al.Adoption of cytoreductive surgery in the management of peritoneal malignancies-Global trends.J Surg Oncol. 2023;128(6):1021-1031. doi:10.1002/jso.27448
10 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Yun WS, Bae JM.Primary peritoneal serous carcinoma, an extremely rare malignancy: a case report and review of the literature.Oncol Lett. 2016;11(6):4063–4065. doi:10.3892/ol.2016.4525Veron Sanchez A, Bennouna I, Coquelet N, et al.Unravelling peritoneal carcinomatosis using cross-sectional imaging modalities.Diagnostics (Basel). 2023;13(13):2253. doi:10.3390/diagnostics13132253National Cancer Institute.Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ)—health professional version.Gao B, Lindemann K, Anderson L, et al.Serous ovarian and primary peritoneal cancers: a comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.Gynecol Oncol. 2016;142(3):458-464. doi:10.1016/j.ygyno.2016.06.023Bintintan VV, Cordoş A, Chira R, et al.The value of staging laparoscopy for optimal multidisciplinary treatment in patients with gastric cancer.Chirurgia (Bucur). 2018;113(6):789-798. doi:10.21614/chirurgia.113.6.789Andikyan V, Kim A, Gretz HF 3rd, et al.Laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction in patients undergoing primary debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer.Am J Clin Oncol. 2018;41(10):938-942. doi:10.1097/COC.0000000000000413Tufts Medical Center.Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).Kurnit KC, Coleman RL, Westin SN.Using PARP inhibitors in the treatment of patients with ovarian cancer.Curr Treat Options Oncol. 2018;19(12):1. doi:10.1007/s11864-018-0572-7Lee J, Turetsky J, Nasri E, Rogers SC.Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.BMJ Case Rep. 2023;16(12):e255916. doi:10.1136/bcr-2023-255916Sedighim S, Khan A, Li AY, et al.Adoption of cytoreductive surgery in the management of peritoneal malignancies-Global trends.J Surg Oncol. 2023;128(6):1021-1031. doi:10.1002/jso.27448
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Yun WS, Bae JM.Primary peritoneal serous carcinoma, an extremely rare malignancy: a case report and review of the literature.Oncol Lett. 2016;11(6):4063–4065. doi:10.3892/ol.2016.4525Veron Sanchez A, Bennouna I, Coquelet N, et al.Unravelling peritoneal carcinomatosis using cross-sectional imaging modalities.Diagnostics (Basel). 2023;13(13):2253. doi:10.3390/diagnostics13132253National Cancer Institute.Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ)—health professional version.Gao B, Lindemann K, Anderson L, et al.Serous ovarian and primary peritoneal cancers: a comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.Gynecol Oncol. 2016;142(3):458-464. doi:10.1016/j.ygyno.2016.06.023Bintintan VV, Cordoş A, Chira R, et al.The value of staging laparoscopy for optimal multidisciplinary treatment in patients with gastric cancer.Chirurgia (Bucur). 2018;113(6):789-798. doi:10.21614/chirurgia.113.6.789Andikyan V, Kim A, Gretz HF 3rd, et al.Laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction in patients undergoing primary debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer.Am J Clin Oncol. 2018;41(10):938-942. doi:10.1097/COC.0000000000000413Tufts Medical Center.Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).Kurnit KC, Coleman RL, Westin SN.Using PARP inhibitors in the treatment of patients with ovarian cancer.Curr Treat Options Oncol. 2018;19(12):1. doi:10.1007/s11864-018-0572-7Lee J, Turetsky J, Nasri E, Rogers SC.Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.BMJ Case Rep. 2023;16(12):e255916. doi:10.1136/bcr-2023-255916Sedighim S, Khan A, Li AY, et al.Adoption of cytoreductive surgery in the management of peritoneal malignancies-Global trends.J Surg Oncol. 2023;128(6):1021-1031. doi:10.1002/jso.27448
Yun WS, Bae JM.Primary peritoneal serous carcinoma, an extremely rare malignancy: a case report and review of the literature.Oncol Lett. 2016;11(6):4063–4065. doi:10.3892/ol.2016.4525
Veron Sanchez A, Bennouna I, Coquelet N, et al.Unravelling peritoneal carcinomatosis using cross-sectional imaging modalities.Diagnostics (Basel). 2023;13(13):2253. doi:10.3390/diagnostics13132253
National Cancer Institute.Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ)—health professional version.
Gao B, Lindemann K, Anderson L, et al.Serous ovarian and primary peritoneal cancers: a comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.Gynecol Oncol. 2016;142(3):458-464. doi:10.1016/j.ygyno.2016.06.023
Bintintan VV, Cordoş A, Chira R, et al.The value of staging laparoscopy for optimal multidisciplinary treatment in patients with gastric cancer.Chirurgia (Bucur). 2018;113(6):789-798. doi:10.21614/chirurgia.113.6.789
Andikyan V, Kim A, Gretz HF 3rd, et al.Laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction in patients undergoing primary debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer.Am J Clin Oncol. 2018;41(10):938-942. doi:10.1097/COC.0000000000000413
Tufts Medical Center.Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).
Kurnit KC, Coleman RL, Westin SN.Using PARP inhibitors in the treatment of patients with ovarian cancer.Curr Treat Options Oncol. 2018;19(12):1. doi:10.1007/s11864-018-0572-7
Lee J, Turetsky J, Nasri E, Rogers SC.Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.BMJ Case Rep. 2023;16(12):e255916. doi:10.1136/bcr-2023-255916
Sedighim S, Khan A, Li AY, et al.Adoption of cytoreductive surgery in the management of peritoneal malignancies-Global trends.J Surg Oncol. 2023;128(6):1021-1031. doi:10.1002/jso.27448
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
